vs
KKR Real Estate Finance Trust Inc.（KREF）与Sight Sciences, Inc.（SGHT）财务数据对比。点击上方公司名可切换其他公司
KKR Real Estate Finance Trust Inc.的季度营收约是Sight Sciences, Inc.的1.3倍（$25.8M vs $20.4M），Sight Sciences, Inc.净利率更高（-20.4% vs -101.7%，领先81.3%），Sight Sciences, Inc.同比增速更快（6.9% vs -26.6%），过去两年Sight Sciences, Inc.的营收复合增速更高（2.9% vs -18.8%）
KKR房地产金融信托公司是全球投资机构KKR旗下的专业房地产金融平台，主要发起、收购并管理优先担保商业地产贷款组合，抵押物多为美国各地的优质机构级商业地产，通过贷款利息收入为投资者提供稳定的经风险调整后的回报。
Sight Sciences, Inc.是一家处于商业化阶段的医疗科技企业，专注于开发及商业化青光眼、干眼症等常见眼部疾病的创新治疗产品，提供微创手术设备与非手术护理解决方案，主要服务美国市场的眼科医师及患者。
KREF vs SGHT — 直观对比
营收规模更大
KREF
是对方的1.3倍
$20.4M
营收增速更快
SGHT
高出33.5%
-26.6%
净利率更高
SGHT
高出81.3%
-101.7%
两年增速更快
SGHT
近两年复合增速
-18.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $25.8M | $20.4M |
| 净利润 | $-26.2M | $-4.2M |
| 毛利率 | — | 87.3% |
| 营业利润率 | -105.1% | -18.0% |
| 净利率 | -101.7% | -20.4% |
| 营收同比 | -26.6% | 6.9% |
| 净利润同比 | -229.6% | 64.9% |
| 每股收益（稀释后） | $-0.49 | $-0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KREFSGHT
| Q4 25 | $25.8M | $20.4M | ||
| Q3 25 | $25.3M | $19.9M | ||
| Q2 25 | $30.2M | $19.6M | ||
| Q1 25 | $31.3M | $17.5M | ||
| Q4 24 | $35.1M | $19.1M | ||
| Q3 24 | $37.0M | $20.2M | ||
| Q2 24 | $40.4M | $21.4M | ||
| Q1 24 | $39.1M | $19.3M |
净利润KREFSGHT
| Q4 25 | $-26.2M | $-4.2M | ||
| Q3 25 | $13.8M | $-8.2M | ||
| Q2 25 | $-29.7M | $-11.9M | ||
| Q1 25 | $-4.9M | $-14.2M | ||
| Q4 24 | $20.3M | $-11.8M | ||
| Q3 24 | $-7.4M | $-11.1M | ||
| Q2 24 | $25.8M | $-12.3M | ||
| Q1 24 | $-3.1M | $-16.3M |
毛利率KREFSGHT
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
营业利润率KREFSGHT
| Q4 25 | -105.1% | -18.0% | ||
| Q3 25 | 50.4% | -39.7% | ||
| Q2 25 | -101.3% | -59.6% | ||
| Q1 25 | -18.3% | -79.2% | ||
| Q4 24 | 55.8% | -62.5% | ||
| Q3 24 | -19.6% | -55.7% | ||
| Q2 24 | 63.3% | -59.2% | ||
| Q1 24 | -8.7% | -76.4% |
净利率KREFSGHT
| Q4 25 | -101.7% | -20.4% | ||
| Q3 25 | 54.4% | -41.0% | ||
| Q2 25 | -98.5% | -61.0% | ||
| Q1 25 | -15.5% | -80.8% | ||
| Q4 24 | 57.7% | -62.1% | ||
| Q3 24 | -20.0% | -54.9% | ||
| Q2 24 | 63.9% | -57.7% | ||
| Q1 24 | -7.9% | -84.4% |
每股收益（稀释后）KREFSGHT
| Q4 25 | $-0.49 | $-0.07 | ||
| Q3 25 | $0.12 | $-0.16 | ||
| Q2 25 | $-0.53 | $-0.23 | ||
| Q1 25 | $-0.15 | $-0.28 | ||
| Q4 24 | $0.22 | $-0.23 | ||
| Q3 24 | $-0.19 | $-0.22 | ||
| Q2 24 | $0.29 | $-0.25 | ||
| Q1 24 | $-0.13 | $-0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $84.6M | $92.0M |
| 总债务越低越好 | — | $42.4M |
| 股东权益账面价值 | $1.2B | $63.9M |
| 总资产 | $6.5B | $115.3M |
| 负债/权益比越低杠杆越低 | — | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资KREFSGHT
| Q4 25 | $84.6M | $92.0M | ||
| Q3 25 | $204.1M | $92.4M | ||
| Q2 25 | $107.7M | $101.5M | ||
| Q1 25 | $106.4M | $108.8M | ||
| Q4 24 | $104.9M | $120.4M | ||
| Q3 24 | $108.8M | $118.6M | ||
| Q2 24 | $107.2M | $118.2M | ||
| Q1 24 | $106.5M | $127.3M |
总债务KREFSGHT
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
股东权益KREFSGHT
| Q4 25 | $1.2B | $63.9M | ||
| Q3 25 | $1.2B | $64.3M | ||
| Q2 25 | $1.2B | $70.0M | ||
| Q1 25 | $1.3B | $77.6M | ||
| Q4 24 | $1.3B | $87.5M | ||
| Q3 24 | $1.4B | $95.0M | ||
| Q2 24 | $1.4B | $101.6M | ||
| Q1 24 | $1.4B | $109.2M |
总资产KREFSGHT
| Q4 25 | $6.5B | $115.3M | ||
| Q3 25 | $6.5B | $116.3M | ||
| Q2 25 | $6.8B | $122.0M | ||
| Q1 25 | $6.6B | $129.7M | ||
| Q4 24 | $6.4B | $142.8M | ||
| Q3 24 | $6.8B | $143.6M | ||
| Q2 24 | $7.1B | $149.7M | ||
| Q1 24 | $7.3B | $155.6M |
负债/权益比KREFSGHT
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $72.3M | $-1.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-2.0M |
| 自由现金流率自由现金流/营收 | — | -9.7% |
| 资本支出强度资本支出/营收 | — | 0.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流KREFSGHT
| Q4 25 | $72.3M | $-1.8M | ||
| Q3 25 | $18.5M | $-8.7M | ||
| Q2 25 | $21.1M | $-7.5M | ||
| Q1 25 | $15.9M | $-11.6M | ||
| Q4 24 | $132.6M | $-3.5M | ||
| Q3 24 | $49.1M | $362.0K | ||
| Q2 24 | $30.6M | $-9.5M | ||
| Q1 24 | $34.5M | $-9.8M |
自由现金流KREFSGHT
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-8.9M | ||
| Q2 25 | — | $-7.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-3.6M | ||
| Q3 24 | — | $311.0K | ||
| Q2 24 | — | $-9.5M | ||
| Q1 24 | — | $-9.9M |
自由现金流率KREFSGHT
| Q4 25 | — | -9.7% | ||
| Q3 25 | — | -44.7% | ||
| Q2 25 | — | -39.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -18.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | -44.7% | ||
| Q1 24 | — | -51.4% |
资本支出强度KREFSGHT
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.6% |
现金转化率KREFSGHT
| Q4 25 | — | — | ||
| Q3 25 | 1.34× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.54× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.19× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KREF
暂无分部数据
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
